Regulation of transformed state by calpastatin via PKCepsilon in NIH3T3 mouse fibroblasts. 2002

Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
Department of Biochemistry, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba 260-8670, Japan. hiwasa@med.m.chiba-u.ac.jp

Ca(2+)-activated neutral protease calpain is ubiquitously expressed and may have pleiotropic biological functions. We have previously reported that repeated treatment of NIH3T3 mouse fibroblasts with the calpain inhibitor N-acetyl-Leu-Leu-norleucinal (ALLN) resulted in the induction of transformed foci [T. Hiwasa, T. Sawada, and S. Sakiyama (1990) Carcinogenesis 11, 75-80]. To elucidate further the effects of calpain in malignant transformation of NIH3T3 cells, calpastatin, an endogenous specific inhibitor of calpain, was expressed in NIH3T3 cells by transfection with cDNA. G418-selected calpastatin-expressing clones showed a significant increase in the anchorage-independent growth ability. A similar increase in cloning efficiency in soft agar medium was also observed in calpain small-subunit-transfected clones. On the other hand, reduced expression of calpastatin achieved by transfection with calpastatin antisense cDNA in Ha-ras-transformed NIH3T3 (ras-NIH) cells caused morphological reversion as well as a decrease in anchorage-independent growth. When NIH3T3 cells were treated with ALLN for 3 days, cell growth was stimulated by approximately 10%. This growth stimulation by ALLN was not observed in ras-NIH cells, but recovered by expression of a dominant negative form of protein kinase C (PKC)epsilon but not by that of PKCalpha. Western blotting analysis showed that an increase in PKCepsilon was much more prominent than that of PKCalpha in NIH3T3 cells after treatment with ALLN. These results are concordant with the notion that calpain suppresses malignant transformation by predominant degradation of PKCepsilon.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D007976 Leupeptins A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002135 Calcium-Binding Proteins Proteins to which calcium ions are bound. They can act as transport proteins, regulator proteins, or activator proteins. They typically contain EF HAND MOTIFS. Calcium Binding Protein,Calcium-Binding Protein,Calcium Binding Proteins,Binding Protein, Calcium,Binding Proteins, Calcium,Protein, Calcium Binding,Protein, Calcium-Binding
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D005799 Genes, Dominant Genes that influence the PHENOTYPE both in the homozygous and the heterozygous state. Conditions, Dominant Genetic,Dominant Genetic Conditions,Genetic Conditions, Dominant,Condition, Dominant Genetic,Dominant Gene,Dominant Genes,Dominant Genetic Condition,Gene, Dominant,Genetic Condition, Dominant

Related Publications

Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
June 2015, Physiological reports,
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
October 1986, The EMBO journal,
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
October 2003, International journal of oncology,
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
January 2002, Journal of cellular biochemistry,
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
January 2003, Advances in experimental medicine and biology,
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
August 1987, Experimental cell research,
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
January 1992, Growth factors (Chur, Switzerland),
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
May 2007, International journal of molecular medicine,
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
January 1981, Medical microbiology and immunology,
Takaki Hiwasa, and Mitsuyuki Nakata, and Miho Nakata, and Shigeo Ohno, and Masatoshi Maki, and Koichi Suzuki, and Masaki Takiguchi
September 1984, Experimental cell research,
Copied contents to your clipboard!